Quick Answer
Matinas BioPharma Holdings, Inc. reported R&D Expense of $85.0 thousand for fiscal year 2025.
Matinas BioPharma Holdings, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $85.0K | -99.3% |
| 2024 | $11.43M | -21.1% |
| 2023 | $14.49M | -13.1% |
| 2022 | $16.68M | +14.4% |
| 2021 | $14.58M | +1.6% |
| 2020 | $14.36M | +27.8% |
| 2019 | $11.23M | +65.5% |
| 2018 | $6.79M | -24.7% |
| 2017 | $9.01M | +128.3% |
| 2016 | $3.95M | -25.4% |
| 2015 | $5.29M | +2.3% |
| 2014 | $5.18M | +193.8% |
| 2013 | $1.76M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| March 31, 2025 | $85.0K | -97.5% | -96.2% |
| September 30, 2024 | $2.24M | -32.0% | -33.6% |
| June 30, 2024 | $3.37M | -5.3% | -2.2% |
| March 31, 2024 | $3.45M | -13.2% | +4.6% |
| September 30, 2023 | $3.29M | -11.1% | -7.4% |
| June 30, 2023 | $3.56M | -13.8% | -10.4% |
| March 31, 2023 | $3.97M | -20.2% | +7.1% |
| September 30, 2022 | $3.71M | -19.8% | -10.2% |
- Matinas BioPharma Holdings, Inc. showed a decrease of -99.3% in R&D Expense compared to the prior fiscal year.
- Over the 2013–2025 period, Matinas BioPharma Holdings, Inc.’s r&d expense has declined by 95.2% (from $1.76 million to $85.0 thousand).
- The most recent figure is from Matinas BioPharma Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: